Christophe Blockeel Selected Research

Ovarian Hyperstimulation Syndrome

1/2022	A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
1/2022	Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study).
7/2020	The performance of the Elecsys® anti-Müllerian hormone assay in predicting extremes of ovarian response to corifollitropin alfa.
4/2019	A Second Dose of GnRHa in Combination with Luteal GnRH Antagonist May Eliminate Ovarian Hyperstimulation Syndrome in Women with ≥30 Follicles Measuring ≥11 mm in Diameter on Trigger Day and/or Pre-trigger Peak Estradiol Exceeding 10 000 pg/mL.
3/2019	Rare genetic variants potentially involved in ovarian hyperstimulation syndrome.
1/2018	Added value today of hormonal measurements in ovarian stimulation in gonadotropin-releasing hormone antagonist treatment cycle.
7/2015	Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and "freeze-all": in-depth analysis of genetic predisposition.
9/2013	Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
1/2011	Gene expression profile in the endometrium on the day of oocyte retrieval after ovarian stimulation with low-dose hCG in the follicular phase.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christophe Blockeel Research Topics

Disease

9	Ovarian Hyperstimulation Syndrome 01/2022 - 01/2011
5	Spontaneous Abortion (Miscarriage) 07/2023 - 01/2020
4	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 05/2024 - 07/2015
2	Birth Weight (Birth Weights) 02/2024 - 09/2023
2	Genetic Predisposition to Disease (Genetic Predisposition) 03/2019 - 07/2015
2	Vitamin D Deficiency 01/2017 - 01/2016
1	Amenorrhea 05/2024
1	Hypertension (High Blood Pressure) 05/2024
1	Insulin Resistance 05/2024
1	Obesity 05/2024
1	Oligomenorrhea 05/2024
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 05/2024
1	Dyslipidemias (Dyslipidemia) 05/2024
1	Drug-Related Side Effects and Adverse Reactions 01/2022
1	Body Weight (Weight, Body) 01/2022
1	Infertility (Sterility) 10/2021
1	Ovarian Torsion 06/2021
1	Endometriosis 10/2018
1	Hemorrhage 11/2016
1	Avitaminosis (Vitamin Deficiency) 01/2016
1	Ascites 07/2015
1	Cysts 01/2011
1	Polycythemia (Erythrocytosis) 09/2005
1	Myoma 09/2005

Drug/Important Bio-Agent (IBA)

8	Gonadotropin-Releasing Hormone (GnRH)FDA Link 09/2023 - 01/2011
4	Progesterone FDA LinkGeneric 09/2023 - 01/2020
3	Hormones (Hormone)IBA 07/2023 - 01/2016
2	follitropin deltaIBA 01/2022 - 01/2022
2	Estradiol (Delestrogen)FDA LinkGeneric 04/2019 - 01/2018
1	Glucose (Dextrose)FDA LinkGeneric 05/2024
1	LipidsIBA 05/2024
1	Gonadal Steroid Hormones (Sex Hormones)IBA 05/2024
1	Mitochondrial DNA (mtDNA)IBA 02/2024
1	N 30IBA 01/2022
1	Testosterone (Sustanon)FDA Link 10/2021
1	GonadotropinsIBA 06/2021
1	imidazole mustard (BIC)IBA 03/2021
1	AntralIBA 07/2020
1	Messenger RNA (mRNA)IBA 01/2017
1	Calcitriol Receptors (Calcitriol Receptor)IBA 01/2017
1	Vitamin D FDA LinkGeneric 01/2016
1	Clomiphene (Clomifene)FDA LinkGeneric 01/2016
1	AlbuminsIBA 07/2015
1	Cabergoline FDA LinkGeneric 07/2015
1	IronIBA 09/2005

Therapy/Procedure

2	Ovariectomy (Oophorectomy) 06/2021 - 07/2020
1	Cardiopulmonary Resuscitation (CPR) 01/2023
1	Hysterectomy 09/2005